Oksana Koneva

Michael Taylor: UTHR positioned for major new product story in 2027

Michael Taylor: UTHR positioned for major new product story in 2027
UTHR could launch major product in 2027

Michael Taylor, co-founder and portfolio manager at Agora Trading, highlights that UTHR may have an important new product story emerging in 2027.

He also humorously remarks about the possibility of a pig that could solve organ transplant challenges.

Taylor has recently commented on AQRT’s Phase 2 Vitiligo study targeting a $1 billion market in 2026. He has also covered the $2 billion preferred convertible agreement between Summit Therapeutics and AstraZeneca in lung cancer therapies. These updates reflect Taylor’s ongoing focus on new product developments and major biotech transactions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.